KNSA
HealthcareKiniksa Pharmaceuticals, Ltd. · Biotechnology · $4B
What is Kiniksa Pharmaceuticals, Ltd.?
Kiniksa Pharmaceuticals is a mid-cap biopharmaceutical company focused on developing and commercializing medicines for patients with serious, underserved inflammatory and autoimmune conditions. Incorporated in 2018 and headquartered in Hamilton, Bermuda, Kiniksa targets diseases where existing treatment options remain limited.
Kiniksa discovers, acquires, develops, and commercializes therapeutic medicines for debilitating diseases with significant unmet medical needs. Its lead commercial product, ARCALYST, targets recurrent pericarditis — a painful inflammatory cardiovascular condition. Beyond its commercial stage, Kiniksa advances a pipeline of monoclonal antibody candidates addressing giant cell arteritis, prurigo nodularis, and autoimmune pathways involving T-cell and B-cell signaling. Revenue is generated primarily through ARCALYST sales while the pipeline matures through clinical development.
Kiniksa Pharmaceuticals was incorporated in 2018 and is headquartered in Hamilton, Bermuda.
- ARCALYST — approved therapy for recurrent pericarditis
- Mavrilimumab — monoclonal antibody in development for giant cell arteritis
- Vixarelimab — Phase 2a candidate for prurigo nodularis
- KPL-404 — investigational antibody targeting CD40-CD154 autoimmune pathway
Is KNSA a Good Stock to Buy?
UQS Score rates KNSA as Good overall, reflecting a mixed but evolving profile across its five analytical pillars.
KNSA's most notable strengths lie in its Growth and Risk pillars, both rated Strong. The company's commercial launch of ARCALYST has driven meaningful revenue expansion, and its balance sheet profile supports continued pipeline investment without near-term financial distress concerns.
The Moat pillar registers as Weak, reflecting the competitive and patent-sensitive nature of biopharma markets. Valuation is rated Elevated, suggesting the market may already be pricing in optimistic outcomes.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does KNSA pay dividends?
No — Kiniksa Pharmaceuticals, Ltd. does not currently pay a dividend.
Kiniksa Pharmaceuticals does not currently pay a dividend. This is typical for clinical-stage and early-commercial biopharmaceutical companies, which generally reinvest available capital into research, clinical trials, and commercial infrastructure rather than returning cash to shareholders.
When does KNSA report earnings?
Kiniksa Pharmaceuticals reports earnings on a quarterly cadence, consistent with US-listed equities.
The company's commercial progress with ARCALYST has been a key narrative in recent quarters, with growth in net product revenues drawing investor attention. Pipeline readouts and operating expense management also feature prominently in quarterly updates.
For the most recent quarter's results and guidance, visit Kiniksa Pharmaceuticals' investor relations page directly.
KNSA Price History
+211.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Kiniksa Pharmaceuticals, Ltd.?
Based on Kiniksa Pharmaceuticals, Ltd.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
KNSA Long-term Outlook
KNSA's Strong Growth pillar suggests the business is expanding at a pace that stands out relative to many peers in the biopharma space. The Strong Risk pillar adds a degree of financial resilience to that growth story. However, the Elevated Valuation pillar indicates that much of the near-term optimism may already be reflected in the share price, leaving less room for error if clinical or commercial milestones disappoint.
Growth drivers
- Continued commercial uptake of ARCALYST in recurrent pericarditis
- Pipeline advancement of monoclonal antibody candidates into later-stage trials
- Potential label expansions or new indications for existing assets
Key risks
- Elevated valuation leaves limited margin of safety if growth slows
- Weak Moat rating reflects vulnerability to competitive entrants and patent cliffs
- Clinical trial failures could materially reset growth expectations
KNSA vs Peers
Kiniksa operates in a competitive biopharma landscape alongside companies pursuing similar immunology and precision medicine strategies.
Beam focuses on base-editing gene therapy platforms, representing a fundamentally different scientific approach to treating genetic and immune diseases.
Tango pursues precision oncology through synthetic lethality, targeting cancer vulnerabilities rather than inflammatory or autoimmune pathways.
Alumis is developing selective TYK2 inhibitors for autoimmune diseases, competing more directly with Kiniksa in the inflammatory disease space.
Frequently Asked Questions
What does Kiniksa Pharmaceuticals do?
Kiniksa Pharmaceuticals discovers, develops, and commercializes medicines for patients with serious inflammatory and autoimmune diseases. Its commercial product ARCALYST treats recurrent pericarditis, while its pipeline includes monoclonal antibody candidates targeting giant cell arteritis, prurigo nodularis, and other immune-mediated conditions.
Does KNSA pay dividends?
No, Kiniksa Pharmaceuticals does not currently pay a dividend. The company reinvests capital into clinical development and commercial operations, which is standard practice for early-commercial biopharmaceutical companies building out their product portfolios.
When does KNSA report earnings?
Kiniksa reports earnings on a quarterly cadence, as is typical for US-listed companies. For exact dates and the most recent results, check the investor relations section of Kiniksa's official website.
Is KNSA a good stock to buy?
UQS Score rates KNSA as Good overall. The Growth and Risk pillars are both Strong, but the Moat pillar is Weak and Valuation is Elevated. Whether KNSA fits your portfolio depends on your risk tolerance and investment horizon — the full pillar breakdown is available to Pro members.
Is KNSA overvalued?
UQS Score's Valuation pillar for KNSA is rated Elevated, suggesting the current market price may reflect optimistic assumptions about future growth. Investors should weigh this against the company's Strong Growth profile when forming their own view.
How does KNSA compare to its competitors?
Kiniksa competes in the broader biopharma and immunology space alongside companies like Beam Therapeutics, Tango Therapeutics, and Alumis. Each pursues distinct scientific platforms — Kiniksa differentiates through its commercial ARCALYST franchise and its monoclonal antibody pipeline targeting inflammatory diseases.
What is KNSA's market cap bracket?
KNSA is classified as a mid-cap stock. This places it in a segment of the market that often balances growth potential with greater operational maturity than smaller micro- or small-cap biotechs, though it remains subject to the volatility typical of clinical-stage biopharma.
Who founded Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals was incorporated in 2018. For detailed founding history and leadership background, the company's official website and SEC filings provide publicly available information.
Is KNSA a long-term quality investment?
From a long-term quality perspective, KNSA's Strong Growth and Risk pillars are encouraging signals. However, the Weak Moat rating suggests the company has not yet established durable competitive advantages that would protect returns over a long horizon. The full UQS analysis is available to Pro members.
What is the main competitive advantage of Kiniksa Pharmaceuticals?
Kiniksa's primary near-term advantage is its approved commercial product ARCALYST, which addresses recurrent pericarditis — a condition with limited prior treatment options. Its pipeline of monoclonal antibodies targeting additional inflammatory pathways could broaden that position if clinical trials succeed.
What sector does KNSA belong to?
KNSA belongs to the Healthcare sector, specifically within biopharmaceuticals. The company focuses on inflammatory and autoimmune diseases, an area of significant research activity and commercial competition across both large pharma and specialty biotech companies.
Is KNSA a growth stock or value stock?
Based on UQS pillar labels, KNSA leans toward the growth side — its Growth pillar is rated Strong while its Valuation pillar is Elevated, meaning investors are paying a premium relative to current fundamentals in anticipation of continued expansion.
Unlock Full KNSA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access complete financial metrics and trend data
- ✓Compare KNSA against sector peers side by side
- ✓See the full risk and valuation breakdown
- ✓Get the complete analyst-style quality report
Pro Analysis
KNSA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 61.3 | 55.4 | 39.0 | 100.0 | 82.4 | 35.7 | +0.1 |
| May 21, 2026 | 61.2 | 55.2 | 39.0 | 100.0 | 82.4 | 35.5 | +0.1 |
| May 15, 2026 | 61.1 | 54.9 | 39.0 | 100.0 | 82.4 | 35.1 | +0.2 |
| May 13, 2026 | 60.9 | 54.5 | 39.0 | 100.0 | 82.4 | 34.6 | -0.1 |
| May 12, 2026 | 61.0 | 54.6 | 39.0 | 100.0 | 82.4 | 34.7 | +0.7 |
| May 7, 2026 | 60.3 | 51.9 | 39.0 | 100.0 | 82.4 | 34.7 | -0.1 |
| May 3, 2026 | 60.4 | 51.9 | 39.0 | 100.0 | 82.4 | 35.2 | -0.4 |
| May 2, 2026 | 60.8 | 51.9 | 39.0 | 100.0 | 82.4 | 38.2 | 0.0 |
| May 1, 2026 | 60.8 | 51.9 | 39.0 | 100.0 | 82.4 | 38.0 | +0.2 |
| Apr 26, 2026 | 60.6 | 51.9 | 39.0 | 100.0 | 82.4 | 36.6 | +0.1 |
KNSA — Pillar Breakdown
Quality
— 55.4/100 (25%)Kiniksa Pharmaceuticals, Ltd. shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 100.0/100 (20%)Kiniksa Pharmaceuticals, Ltd. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 82.4/100 (15%)Kiniksa Pharmaceuticals, Ltd. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 35.7/100 (15%)Kiniksa Pharmaceuticals, Ltd. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 39/100 (25%)Kiniksa Pharmaceuticals, Ltd. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for KNSA.
Score Composition
Financial Data
More Stock Analysis
How is the KNSA UQS Score Calculated?
The UQS (Unified Quality Score) for Kiniksa Pharmaceuticals, Ltd. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Kiniksa Pharmaceuticals, Ltd.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Kiniksa Pharmaceuticals, Ltd. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.